



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|--|---|
| Summary for ARTG Entry: | 374693 | Eurofins Technologies Australia Pty Ltd - Severe acute respiratory syndrome-associated coronavirus IVDs |
| ARTG entry for | Medical Device Included - IVD Class 3 | |
| Sponsor | Eurofins Technologies Australia Pty Ltd | |
| Postal Address | 6 Monterey Road, Dandenong South, VIC, 3175 Australia | |
| ARTG Start Date | 15/09/2021 | |
| Product Category | Medical Device Class 3 | |
| Status | Active | |
| Approval Area | IVD | |

Conditions

- The inclusion of the kind of device in the ARTG is subject to compliance with all conditions placed or imposed on the ARTG entry. Refer Part 4-5, Division 2 (Conditions) of the Therapeutic Goods Act 1989 and Part 5, Division 5.2 (Conditions) of the Therapeutic Goods (Medical Devices) Regulations 2002 for relevant information.
- Breaching conditions of the inclusion related to the device of the kind may lead to suspension or cancellation of the ARTG entry; may be a criminal offence; and civil penalties may apply.

Manufacturers

| Name | Address |
|---------------------------------|---|
| Hangzhou Alltest Biotech Co Ltd | 550# Yin Hai Street Hangzhou Economic & Technological Development Area , Hangzhou, 310018 China |

Products

1 . Severe acute respiratory syndrome-associated coronavirus IVDs

| Product Type | IVD | Effective Date | 7/02/2022 |
|-------------------------|--|----------------|-----------|
| GMDN | CT772 Severe acute respiratory syndrome-associated coronavirus IVDs | | |
| Intended Purpose | Intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19 from symptomatic individuals at the point of care by trained health professionals (nasopharyngeal and nasal swabs) and for self-testing by lay persons (nasal swabs). | | |

Specific Conditions

The following conditions apply to the supply of COVID-19 Self-Tests

Customer support service

(1) The sponsor must provide a telephone helpline or on-line interactive support service that

(a) provides immediate customer support on an individualised basis in relation to the correct use of the device and the interpretation of the test result and

(b) operates between 9 am and 7 pm (AEST), or 9 am and 8 pm (AEDT), 7 days per week.

(2) The sponsor must ensure that telephone helpline and on-line operators providing customer support services mentioned in condition 1

(a) have received training in the correct use and performance of the device, and the interpretation of the test result and

(b) provide advice to users on how to access laboratory PCR testing to confirm a positive test result and

(c) provide advice to users on how to contact relevant local state and territory health department support services including phone lines and websites.

(3) The sponsor must provide simple, clear and effective instructions, in video, pictorial or graphical form, in the correct use and performance of the device, and the interpretation of the test result, on the sponsor's website.

(4) The sponsor must maintain records that demonstrate that the device has been supplied in compliance with conditions 1 and 3, and that it has complied with condition 2, and provide the records to the Secretary on request.

Instructions for use

(5) The sponsor must publish on the sponsor's website, and also provide to the Therapeutic Goods Administration (TGA) for publication on the TGA website any new version of the IFU released by the manufacturer, within 3 business days of the release.

Clinical studies

(6) Within 6 months of inclusion in the ARTG, the sponsor must provide a supplemental clinical study to the TGA, which shows the outcome of testing at least 30 clinical samples collected from individuals that are SARS-CoV-2 positive by RT-PCR for the delta variant.

Complaints

(7) The sponsor must submit all complaints related to the use and performance of the device including, but not limited to, adverse events and reports of false positive and false negative results to the TGA

(a) for the period beginning on the day this condition is imposed, and ending at the conclusion of the next five (5) financial years and

(b) through the Medical Device Incident Reporting Scheme <https://www.tga.gov.au/medical-device-incident-reporting-investigation-scheme-iris> (IRIS) and

(c) as soon as the complaints are received by the sponsor.

Post market surveillance report

(8) The sponsor must provide a post market surveillance report, which includes the following information, to the TGA (at the email address postmarketdevices@health.gov.au) for each reporting period specified in condition 9

(a) the numbers of tests sold both in Australia and overseas

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

- (b) any adverse events, including numbers of any reported false positive or false negative results, both in Australia and overseas
- (c) reported problems, issues or complaints associated with the use or interpretation of the device, both in Australia and overseas.

- (9) For the purposes of condition 8, each of the following is a reporting period
 - (a) the period beginning on the day when this condition is imposed, and ending on the day at the end of that month
 - (b) each subsequent month up until 30 June 2022
 - (c) each of the next three financial years.

- (10) The report mentioned in condition 8, must be given
 - (a) for a reporting period mentioned in paragraph (a) or (b) of condition 9, on or before the last day of the following month
 - (b) for a reporting period mentioned in paragraph (c) of condition 9, before 1 October after that reporting period.

The following conditions apply to COVID-19 rapid antigen point-of-care tests

- (1) The person in whose name the device is included in the Register (the sponsor) may only supply the device to one or more of the following
 - (a) laboratory that is an accredited pathology laboratory within the meaning of the Health Insurance Act 1973
 - (b) a person who is registered under a law of a state or territory to practice pharmacy (a pharmacist), where
 - (i) the pharmacist is responsible for performing or supervising the performance of the test and
 - (ii) the person mentioned in subparagraph (i) and any other person acting under their supervision to perform the test have received training in the correct use of the device and the interpretation of the test result
 - (c) a health practitioner within the meaning of the Therapeutic Goods Act 1989 (other than a pharmacist) or a person registered under a law of a state or territory to practice paramedicine (a paramedic), where
 - (i) the health practitioner or the paramedic is responsible for performing or supervising the performance of the test and
 - (ii) the person mentioned in subparagraph (i) and any other person acting under their supervision to perform the test have received training in the correct use of the device and the interpretation of the test result and
 - (d) a residential care or aged care facility, or a home care service provider, that employs or engages a health practitioner within the meaning of the Therapeutic Goods Act 1989 or a paramedic, where
 - (i) the health practitioner or the paramedic is responsible for performing or supervising the performance of the test and
 - (ii) the person mentioned in subparagraph (i) and any other person acting under their supervision to perform the test have received training in the correct use of the device and the interpretation of the test result and
 - (iii) the device is only used to test employees or contractors of, or a patient under the direct care of, the health practitioner or the paramedic
 - (e) an organisation, business or institution that employs or engages a health practitioner within the meaning of the Therapeutic Goods Act 1989 or a paramedic, where
 - (i) the health practitioner or the paramedic is responsible for performing or supervising the performance of the test and
 - (ii) the person mentioned in subparagraph (i) and any other person acting under their supervision to perform the test have received training in the correct use of the device and the interpretation of the test result and
 - (iii) the device is only used to test residents, employees or contractors of, or visitors to, the residential care or aged care facility, or clients, employees, or contractors of the home care service provider
 - (f) a department of the Commonwealth, state or territory, with responsibility for health, or a department or other agency of the Commonwealth, state or territory acting on its behalf.

- (2) The device must not be supplied for the purpose of self-testing.

- (3) The sponsor of the device must provide training to a person mentioned in subparagraphs 1(b)(ii), 1(c)(ii), 1(d)(ii) or 1(e)(ii) in the correct use of the device and the interpretation of the test result, prior to that person performing or supervising the performance of the test.

- (4) The sponsor must maintain records that demonstrate the device has been supplied in compliance with these conditions.

Within 12 months of approval for inclusion in the ARTG the sponsor must provide to the Therapeutic Goods Administration (TGA) updated documentation and information to demonstrate ongoing evidence of the compliance of the Device(s) with the requirements of Parts 1 and 2 of Schedule 1 - Essential Principles of the Therapeutic Goods (Medical Devices) Regulations 2002, including

- (5) A report of any adverse events, corrective and preventative actions, and customer complaints provided in the context of the number of devices supplied since the introduction of the Device(s) to market in Australia and Worldwide.
- (6) Information regarding any refusals by Regulatory Authorities for the supply of the Device(s) in any other regulatory jurisdictions.
- (7) Further analytical and clinical evidence to support
 - (a) Analytical and clinical performance of the device
 - (b) Device stability (e.g. shelf-life stability, transport stability)
- (8) Instructions for use that provide updated information on the analytical and clinical performance characteristics of the device.
- (9) Evidence of how the user may verify, at the time of use that the device will perform as intended by the manufacturer through the use of controls.
- (10) Within 6 months from the date of receiving this notice, the sponsor must provide a supplemental clinical study to the TGA, which shows the outcome of testing at least 30 clinical samples collected from individuals that are SARS-CoV-2 positive by RT-PCR for the delta variant.

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.